Stay updated with breaking news from Agrx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Agile Therapeutics (NASDAQ:AGRX – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Monday, Zacks.com reports. According to Zacks, “Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive products. The […]
Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) – Stock analysts at Oppenheimer lifted their Q2 2022 earnings per share (EPS) estimates for shares of Agile Therapeutics in a research report issued to clients and investors on Thursday, March 31st. Oppenheimer analyst L. Gershell now forecasts that the specialty pharmaceutical company will post earnings of ($0.10) […]
Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 1,910,000 shares, an increase of 34.5% from the February 28th total of 1,420,000 shares. Based on an average daily volume of 1,100,000 shares, the days-to-cover ratio is currently 1.7 days. […]
Zacks Investment Research upgraded shares of Agile Therapeutics (NASDAQ:AGRX – Get Rating) from a sell rating to a hold rating in a research report released on Tuesday morning, Zacks.com reports. According to Zacks, “Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. It is focused on the development and commercialization of new prescription contraceptive […]
Equities analysts predict that Agile Therapeutics, Inc. (NASDAQ:AGRX – Get Rating) will report ($0.17) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Agile Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.14) and the lowest estimate coming in at ($0.20). Agile […]